Hapoalim Securities is out with a research report on Amarin Corporation plc (ADR) AMRN, and has tripled its price target and is reiterating its Buy rating on shares. It moved its target to $12, up from $4.
In a note sent to clients, Hapoalim writes, "Amarin reported positive top-line results from the AMR101, MARINE study and now expects to file AMR101 with the FDA in 2011. 4g of AMR101 showed a significant median triglyceride (TG) decrease of 33 % (p < 0.0001) versus placebo, and 2g of AMR101 showed a significant median TG decrease of 20 % (p = 0.0051) versus placebo. AMR101 did not result in an increase in median LDL-C compared to placebo at either dose. As a result of the positive MARINE results, we are increasing our Price Target for Amarin from $4 to $12. We reiterate our BUY rating."
Shares of AMRN are up $2.19 to $5.74, a gain of 61.7%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsHapoalim SecuritiesHealth CareIndustrial ConglomeratesIndustrialsPharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in